Denmark organizes executive roundtable at Bio 2012 Conference to
highlight the Danish success of using translational medicine to bring
new drugs faster to market.
NEW YORK, June 15, 2012 /CNW/ - The following is being released by
Invest in Denmark, North America:
The increasing global demand for higher quality and more efficient
healthcare at lower costs will benefit patients, payers, and providers.
An essential part of the roadmap to better healthcare is shortening the
timeframe for development of new treatments by using the right infrastructure to bring new drugs faster to the market and to patients'
Denmark stands out in Europe by embracing the concept of translational
research, having identified it as a key component of the future of
healthcare in the public and private sectors. For many years, Denmark
has been actively working to guarantee the future of its pharma/biotech
industries, with a long history of drug development and a strong
science base. Denmark is amongst the top countries in the world
producing biomedical research per capita.
This is reflected in the next generation of drug companies as well as in
large companies such as Novo Nordisk, Leo Pharma, and Lundbeck. These
companies have worked to ensure the industry's future through
partnering and, most significantly, through the supply of experienced
personnel and management to start-ups. The development in the field of
translational science is part and parcel of this aggressive drive to
cement Denmark's role in the future shift of the drug development
New Danish biobank
Denmark has just launched its National Biobank with more than 15 million
biological specimens, offering unsurpassed opportunities for R&D. www.biobankdenmark.dk
Denmark also has the world's oldest cancer registry, allowing foreign
companies to accelerate R&D by establishing an entity in Denmark.
Several major US life sciences companies already have their eyes on
Agilent has just bought cancer diagnostics company Dako
Abbott has acquired a compound from Danish company Action Pharma
Pfizer Consumer Healthcare acquired Ferrosan last year
More and more US companies have discovered the Danish pipeline of drugs
in development, the 3rd largest in Europe.
Bio 2012: Roundtable with Professor Liselotte Hojgaard and Steven
During the Bio conference, Invest in Denmark is organizing an executive
roundtable on translational medicine on June 19th for major US
biopharma companies. The roundtable will be moderated by Steven Burrill
and includes a recognized frontrunner in the field of translational
medicine, Professor Liselotte Hojgaard from University of Copenhagen.
The roundtable will focus on proven models of collaboration and
infrastructure to improve R&D. The event is by invitation only.
Professor Hojgaard on why Denmark is an optimal location for biotech:
"Denmark is amongst the leaders in biomedical research. This is due to
excellent universities and hospitals, robust funding including success
within the EU system and a strong biomedical industry, and last but not
least the positive attitude towards biotech and health research from
the public and private sectors."
SOURCE Invest in Denmark, North America
For more information, please contact Danish Consulate General, New York,
Mr. Jon Thorgaard, firstname.lastname@example.org; +1 646-509-9726.
For further information: